Evidence map›Paper›PMID 23936087›Full record

ArticlePloS one2013

Challenges in using cultured primary rodent hepatocytes or cell lines to study hepatic HDL receptor SR-BI regulation by its cytoplasmic adaptor PDZK1.

Kosuke Tsukamoto, Lorenna Buck, Walker Inman, Linda Griffith, Olivier Kocher, Monty Krieger

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kosuke TsukamotoDepartment of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America.
Lorenna Buck
Walker Inman
Linda Griffith
Olivier Kocher
Monty Krieger
Massachusetts Institute of Technology · USHarvard University · US

Funding

Systems Biology of Cell Decision ProcessesP50GM068762 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI KEATING, AMY E · 2003 to 2012
$32.3M
Platelets in Cardiovascular Biology and PathologyP01HL066105 · NHLBI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI HYNES, RICHARD O · 2001 to 2010
$28.4M
SCAVENGER RECEPTORS--LIGAND BINDING AND PATHOPHYSIOLOGYR01HL052212 · NHLBI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI KRIEGER, MONTY · 1994 to 2011
$5.4M
Role of PDZK1 in lipid metabolism and atherosclerosis.R01HL077780 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI KOCHER, OLIVIER N. · 2006 to 2016
$4.2M
Bioengineering partnership to improve chemical hazard testing paradigmsR01ES015241 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI RUSYN, IVAN · 2008 to 2012
$3.1M
NHLBI NIH HHS HL052212NHLBI NIH HHS HL066105NHLBI NIH HHS HL077780NHLBI NIH HHS P01 HL066105NHLBI NIH HHS R01 HL052212NHLBI NIH HHS R01 HL077780NIEHS NIH HHS ES015241NIEHS NIH HHS R01 ES015241NIGMS NIH HHS GM068762NIGMS NIH HHS P50 GM068762
6 · The paper itself

Abstract

backgroundPDZK1 is a four PDZ-domain containing cytoplasmic protein that binds to a variety of membrane proteins via their C-termini and can influence the abundance, localization and/or function of its target proteins. One of these targets in hepatocytes in vivo is the HDL receptor SR-BI. Normal hepatic expression of SR-BI protein requires PDZK1 - <5% of normal hepatic SR-BI is seen in the livers of PDZK1 knockout mice. Progress has been made in identifying features of PDZK1 required to control hepatic SR-BI in vivo using hepatic expression of wild-type and mutant forms of PDZK1 in wild-type and PDZK1 KO transgenic mice. Such in vivo studies are time consuming and expensive, and cannot readily be used to explore many features of the underlying molecular and cellular mechanisms. METHODOLOGY/PRINCIPAL

findingsHere we have explored the potential to use either primary rodent hepatocytes in culture using 2D collagen gels with newly developed optimized conditions or PDZK1/SR-BI co-transfected cultured cell lines (COS, HEK293) for such studies. SR-BI and PDZK1 protein and mRNA expression levels fell rapidly in primary hepatocyte cultures, indicating this system does not adequately mimic hepatocytes in vivo for analysis of the PDZK1 dependence of SR-BI. Although PDZK1 did alter SR-BI protein expression in the cell lines, its influence was independent of SR-BI's C-terminus, and thus is not likely to occur via the same mechanism as that which occurs in hepatocytes in vivo. CONCLUSIONS/SIGNIFICANCE: Caution must be exercised in using primary hepatocytes or cultured cell lines when studying the mechanism underlying the regulation of hepatic SR-BI by PDZK1. It may be possible to use SR-BI and PDZK1 expression as sensitive markers for the in vivo-like state of hepatocytes to further improve primary hepatocyte cell culture conditions.

Indexed as

AnimalsCell LineCholesterol EstersCytoplasmHepatocytesHumansIntracellular Signaling Peptides and ProteinsLiverMaleMembrane ProteinsMiceMice, Inbred C57BLMice, KnockoutScavenger Receptors, Class BTime FactorsTransfectionCholesterol EstersIntracellular Signaling Peptides and ProteinsMembrane ProteinsPDZK1 protein, mouseScarb1 protein, mouseScavenger Receptors, Class B

Identifiers

PMID23936087
PMCPMC3720616
OpenAlexW2107001681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.